Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.

The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Key Takeaways
- β’Latest on Enveda secures $311M to bring more nature-derived AI drugs into clinical trials β reported by TechCrunch AI for the news space.
- β’This story was reported by TechCrunch AI, covering developments in the news space.
- β’AI advancements continue to reshape industries β read the full article on TechCrunch AI for complete coverage.
π Continue reading the full article:
Read Full Article on TechCrunch AI βShare this article



